Transgenic Animal Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Gene Gun, PCR, Microinjections, Others), By PCR (Real-Time PCR, Digital PCR Systems, Others), By Technique (DNA Microinjection, Embryonic Stem Cell-Mediated Gene Transfer, Retrovirus-Mediated Gene Transfer and Others), By Application (Recombinant Human Proteins, Monoclonal Antibodies, Xenotransplantation, Others), By Model Organisms (Mice, Rabbit, Cow, Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Organizations, Others), By Company, and By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.18 Billion
CAGR (2026-2031)	10.55%
Fastest Growing Segment	Gene Gun
Largest Market	North America
Market Size (2031)	USD 7.63 Billion

Market Overview

The Global Transgenic Animal Market will grow from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2031 at a 10.55% CAGR. The Global Transgenic Animal Market comprises the commercialization and utilization of organisms whose genetic material has been deliberately modified to incorporate genes from other species, thereby expressing specific, desirable traits for research or production. The primary drivers fueling this market include the escalating demand for predictive animal models to study chronic human diseases and the rising necessity for recombinant proteins and monoclonal antibodies in the biopharmaceutical sector. Furthermore, the continuous refinement of gene-editing technologies serves as a fundamental engine for growth, enabling the efficient generation of animals that precisely mimic complex physiological conditions required for rigorous drug discovery and development programs.

Despite these strong growth factors, the market encounters a significant challenge in the form of stringent ethical regulations and heightened public scrutiny regarding animal welfare, which can substantially delay regulatory approvals and increase compliance costs. Nevertheless, the reliance on these models remains extensive within the scientific community. According to Understanding Animal Research, in 2024, data revealed that 45% of all regulated scientific procedures in Great Britain were specifically conducted for the creation or breeding of genetically altered animals, underscoring the sustained critical volume of this segment in biomedical innovation.

Key Market Drivers

Advancements in Genome Editing and Engineering Technologies represent the foremost catalyst propelling the Global Transgenic Animal Market. The integration of high-precision tools, such as CRISPR-Cas9, has revolutionized the ability to engineer animals with specific genetic modifications, facilitating the development of organisms that possess human-compatible organs or accurate disease phenotypes. This technological maturation has directly attracted substantial investment into the sector, particularly for xenotransplantation applications where genetically modified pigs serve as viable organ donors. According to eGenesis, September 2024, the company secured $191 million in Series D financing to advance its genetically engineered porcine kidney candidate into first-in-human clinical trials, underscoring the commercial confidence in these genomic platforms.

Simultaneously, the market is heavily influenced by the Rising Demand for Predictive Preclinical Human Disease Models. As the prevalence of complex chronic conditions escalates, pharmaceutical developers require sophisticated in vivo systems to screen therapeutic candidates and mitigate late-stage clinical failures. According to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024' report, it was projected that new cancer cases in the United States would exceed 2 million for the first time, highlighting the critical urgency for advanced oncology models. This surge in disease burden drives massive capital allocation toward discovery pipelines that rely on these transgenic organisms. Consequently, according to Merck & Co., in February 2024, the corporation reported a full-year 2023 research and development expenditure of $30.5 billion, reflecting the immense financial scale supporting biomedical innovation and model utilization.

Download Free Sample Report

Key Market Challenges

Stringent ethical regulations and heightened public scrutiny regarding animal welfare constitute a significant impediment to the growth of the Global Transgenic Animal Market. Regulatory frameworks globally are enforcing increasingly rigorous standards, compelling organizations to undergo exhaustive ethical reviews and demonstrate strict adherence to the principles of Replacement, Reduction, and Refinement. These compliance obligations necessitate substantial investment in oversight and documentation, significantly prolonging development timelines and elevating operational costs. Consequently, this environment discourages the expansion of animal-based research and incentivizes the adoption of non-animal alternative methodologies.

The impact of these constraints is directly reflected in recent operational data, which indicates a tangible contraction in the utilization of transgenic models. According to Understanding Animal Research, in 2024, the number of procedures related to the creation and breeding of genetically altered animals in Great Britain decreased by 0.5% compared to the previous year. This decline underscores the correlation between intensifying regulatory pressures and the dampening of market activities, as research institutions and pharmaceutical companies are forced to limit their reliance on these complex biological models due to the mounting ethical and administrative burdens.

Key Market Trends

Strategic Outsourcing of Model Generation to Contract Research Organizations is fundamentally reshaping the operational structure of the transgenic animal market. Pharmaceutical companies are increasingly divesting from capital-intensive in-house breeding programs to mitigate the high fixed costs associated with facility maintenance and regulatory compliance. This transition allows drug developers to convert fixed overhead into variable costs while accessing specialized colonies that require complex husbandry. The financial impact of this operational shift is evident in the recent performance of major service providers who manage these outsourced supply chains. According to Charles River Laboratories, November 2024, in the 'Third-Quarter 2024 Results', revenue for the Research Models and Services segment increased by 5.9% to $197.8 million, demonstrating the industry's growing reliance on external partners for the provision and maintenance of research models.

Simultaneously, the market is witnessing a Surge in Development of Humanized Immuno-Oncology Models designed specifically to evaluate complex immunotherapies. Unlike traditional transgenic organisms, these specialized platforms are engineered to host functional human immune systems, enabling researchers to test the efficacy of checkpoint inhibitors and antibody-drug conjugates in a systemic environment. This trend is distinct from general disease modeling as it focuses on the precise reconstitution of human immunological responses within the animal host to reduce translational failure rates. The commercial expansion of this niche is substantiated by the growth of companies dedicated to these oncology platforms. According to Champions Oncology, December 2024, in the 'Financial Results for Second Quarter Fiscal 2025', the company reported a total revenue increase of 17% to $13.5 million, reflecting the intensifying uptake of these specialized oncology solutions by the biopharmaceutical sector.

Segmental Insights

The Gene Gun segment is recognized as the fastest growing category in the Global Transgenic Animal Market, driven by its high efficiency in delivering DNA vaccines and therapeutic agents. This method is increasingly utilized because it facilitates direct gene transfer into various tissue types without requiring viral vectors, effectively mitigating risks related to viral toxicity and host immune responses. Consequently, the heightened focus on developing safe transgenic models for biomedical research and pharmaceutical development continues to fuel the widespread adoption of this biolistic technology.

Regional Insights

North America maintains a dominant position in the Global Transgenic Animal Market, driven by extensive investments in biomedical research and a strong concentration of pharmaceutical companies. The region leads in the adoption of transgenic models for drug discovery, particularly in pre-clinical trials and chronic disease studies. This growth is supported by a defined regulatory environment, where agencies like the U.S. Food and Drug Administration (FDA) oversee the approval and safety of genetically altered animals. Consequently, the combination of advanced research capabilities and clear compliance guidelines secures North America’s status as the primary hub for this industry.

Recent Developments

• In October 2025, GemPharmatech announced a research collaboration with Memorial Sloan Kettering Cancer Center to advance the discovery of novel therapeutic antibodies. The partnership focused on utilizing the company’s NeoMab platform, a sophisticated transgenic mouse model genetically engineered to express a broad repertoire of fully human variable heavy and light chain antibodies. This collaboration allowed researchers to leverage the platform's high-throughput capabilities to identify potent antibody candidates for oncology targets efficiently. By eliminating the need for subsequent humanization, the initiative aimed to significantly shorten development timelines for new cancer immunotherapies.
• In June 2025, Taconic Biosciences entered into an exclusive license agreement with Helmholtz Munich, a leading biomedical research center, to expand its portfolio of gene-editing services. This strategic partnership granted the company rights to utilize advanced CRISPR/Cas9 technologies developed by the institute, specifically optimized for the precise generation of genetically modified animal models. By integrating these cutting-edge methodologies into its existing ExpressMODEL platform, the company aimed to accelerate the production of complex transgenic rodent models. This collaboration strengthened the company's ability to provide high-quality, custom-designed tools essential for preclinical drug discovery and disease research.
• In April 2024, United Therapeutics announced that its subsidiary had successfully facilitated the first-ever transplant of a Xenothymokidney into a living human patient. The investigational organ consisted of a gene-edited pig kidney combined with the donor animal's thymus tissue, a strategy intended to modulate the recipient's immune response and prevent rejection. This significant development in the transgenic animal market leveraged the company’s GalSafe pig platform, which is engineered to eliminate specific sugars that trigger immune attacks. The procedure marked a critical step toward the commercialization of xenotransplantation products for life-saving clinical applications.
• In March 2024, eGenesis, a biotechnology company focused on xenotransplantation, achieved a historic milestone by announcing the world's first successful transplant of a genetically engineered porcine kidney into a living human recipient. The procedure, authorized by the FDA under the Expanded Access pathway, utilized a donor organ featuring 69 genomic edits designed to remove porcine retroviruses and enhance compatibility with the human immune system. This breakthrough demonstrated the potential of the company's proprietary transgenic platform to address the global organ shortage, providing a viable alternative for patients with end-stage renal disease who lack other therapeutic options.

Key Market Players

• C.H. Boehringer Sohn Ko. KG
• ELIAS Animal Health, LLC
• Zoetis Inc.
• AB Science S.A.
• Karyopharm Therapeutics, Inc.
• Vivesto AB
• Merial Inc.
• Elanco Animal Health, Inc.
• Dechra Pharmaceuticals PLC
• Torigen Pharmaceuticals Inc

By Product	By PCR	By Technique	By Application	By Model Organisms	By End User	By Region
Gene Gun PCR Microinjections Others	Real-Time PCR Digital PCR Systems Others	DNA Microinjection Embryonic Stem Cell-Mediated Gene Transfer Retrovirus-Mediated Gene Transfer and Others	Recombinant Human Proteins Monoclonal Antibodies Xenotransplantation Others	Mice Rabbit Cow Others	Biotechnology & Pharmaceutical Companies Academic & Research Organizations Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Transgenic Animal Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Transgenic Animal Market, By Product:

• Gene Gun
• PCR
• Microinjections
• Others

• Transgenic Animal Market, By PCR:

• Real-Time PCR
• Digital PCR Systems
• Others

• Transgenic Animal Market, By Technique:

• DNA Microinjection
• Embryonic Stem Cell-Mediated Gene Transfer
• Retrovirus-Mediated Gene Transfer and Others

• Transgenic Animal Market, By Application:

• Recombinant Human Proteins
• Monoclonal Antibodies
• Xenotransplantation
• Others

• Transgenic Animal Market, By Model Organisms:

• Mice
• Rabbit
• Cow
• Others

• Transgenic Animal Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Organizations
• Others

• Transgenic Animal Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE